Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02361346
Recruitment Status : Recruiting
First Posted : February 11, 2015
Last Update Posted : July 29, 2019
Sponsor:
Information provided by (Responsible Party):
Molecular Templates, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.

Condition or disease Intervention/treatment Phase
Non-Hodgkin's B-cell Lymphoma Leukemia, Lymphocytic, Chronic, B-Cell Small Lymphocytic Leukemia Diffuse Large B Cell Lymphoma Blood Cancer Hematological Malignancy Drug: MT-3724 Phase 1 Drug: MT-3724 Phase 2 Phase 1 Phase 2

Detailed Description:

This is a three-part Phase 2 study

Part 1: (MT-3724 Dose Escalation) Define the maximum tolerated dose (MTD) of MT-3724 [Completed]

Part 2: (MTD Expansion Cohort) Confirm the safety and tolerability of the MTD of MT-3724 in the MTD Expansion Cohort.

Part 3: (Phase 2 MTD Expansion Cohort) Determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the revised Lugano Classification for Lymphoma adjusted according to LYRIC.

It is anticipated that up to 100 patients will be enrolled in Part 3. Treatment will continue for up to six 21 days cycles. If the subject exhibits SD, CR or PR after the end of Cycle 6 and the investigator determines that the benefit-risk ratio is favorable, then the treatment with MT-3724 may be continued after discussion with the sponsor.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Study Start Date : February 2015
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : September 2021


Arm Intervention/treatment
Experimental: MT-3724 Phase 1 5 mcg/kg/dose
Phase 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 10 mcg/kg/dose
Phase 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 20 mcg/kg/dose
Phase 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 50 mcg/kg/dose
Phase 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 100 mcg/kg/dose
Phase 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 75 mcg/kg/dose
Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1b 50 mcg/kg/dose
Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724
Drug: MT-3724 Phase 1
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 2 50 mcg/kg/dose
Phase 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
Drug: MT-3724 Phase 2
Intravenous dosing on M-W-F x 2 weeks; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.




Primary Outcome Measures :
  1. Tolerability as measured by number of subjects with dose limiting toxicities [ Time Frame: 28 days (Part 1), 21 Days (Part 2 and Part 3) ]
    Evaluation of tolerability of MT-3724 measured by number of subjects with dose limiting toxicities (DLTs)

  2. Safety as measured by number of subjects with Adverse Events using CTCAE [ Time Frame: 28 days (Part 1); 21 days (Part 2) ]
    Safety measured by number of subjects with Adverse Events using CTCAE Version 4.03 (Part 1 and 2)

  3. Efficacy of MT-3724 (Part 3) [ Time Frame: Time Frame: up to 47 weeks (baseline, every 6 weeks during treatment and at the end of treatment visit, which should occur 10-14 days after the last dose) ]
    Determine the efficacy of MT-3724 based on the overall response rate (ORR) by the revised Lugano Classification for Lymphoma adjusted according to LYRIC (lymphoma response to immunomodulatory therapy criteria) (Cheson et al, 2014, 2016). Overall response rate is defined as the proportion of subjects with either a CR or a PR as determined by independent, blinded central review.


Secondary Outcome Measures :
  1. PK Assessment of MT-3724 by Cmax [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    Cmax is the maximum observed serum concentration of free MT-3724 include

  2. PK Assessment of MT-3724 by tmax [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    tmax is the time to maximum observed serum concentration of free MT-3724

  3. PK Assessment of MT-3724 by AUC0-4 [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    AUC0-4 is area under the concentration versus time curve (AUC) from time zero to 4 hours after the end of infusion

  4. PK Assessment of MT-3724 by AUC0-inf [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    AUC0-inf is area under the concentration versus time curve (AUC) from time zero extrapolated to infinity

  5. PK Assessment of MT-3724 by AUClast [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    AUClast is area under the concentration versus time curve (AUC) from time zero to the last sampling time point within the dosing interval

  6. PK Assessment of MT-3724 by t1/2 [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    t1/2 is elimination half-life

  7. PK Assessment of MT-3724 by Vz [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    Vz is a volume of distribution

  8. PK Assessment of MT-3724 by CL [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)] ]
    CL is clearance

  9. PD as measured by clinical symptoms, immunogenicity [ Time Frame: Days 1, 5, 8, 12, 23 and 28 (Part 1, 1 cycle-28 days; and Part 2, 21-day cycles); Day 1 and Day 12 of Cycle 1 (each day is 21 cycles) (Part 3)]Days 1, 5, 8, 12, 23, and 28 (Part 1 and 2); Day 1, Day 12 of Cycle 1 (Part 3) ]
    Evaluation of the pharmacodynamic profile of MT-3724

  10. Efficacy of MT-3724 (Part 3) as based on ORR [ Time Frame: up to 47 weeks (baseline, every 6 weeks during treatment and at the end of treatment visit, which should occur 10-14 days after the last dose) ]
    ORR defined as the proportion of subjects with either a CR or a PR as determined by investigator assessment determined by investigator assessment

  11. Efficacy of MT-3724 (Part 3) as based on DOR [ Time Frame: up to 47 weeks (baseline, every 6 weeks during treatment and at the end of treatment visit, which should occur 10-14 days after the last dose) ]
    Time from initial documentation of tumor response (PR or CR) to disease progression.

  12. Efficacy of MT-3724 (Part 3) as based on DCR [ Time Frame: up to 47 weeks (baseline, every 6 weeks during treatment and at the end of treatment visit, which should occur 10-14 days after the last dose) ]
    Description: Percentage of subjects who have achieved CR, PR and SD (defined as SD for 3 months or longer).

  13. Efficacy of MT-3724 (Part 3)as based on PFS [ Time Frame: up to 47 weeks (baseline, every 6 weeks during treatment and at the end of treatment visit, which should occur 10-14 days after the last dose) ]
    PFS is defined as the time from study enrollment to the earliest date of disease progression or death from any cause.

  14. Efficacy of MT-3724 (Part 3) as based on OS [ Time Frame: up to 47 weeks (baseline, every 6 weeks during treatment and at the end of treatment visit, which should occur 10-14 days after the last dose) ]
    Overall survival is defined as the time from study enrollment to death from any cause

  15. PD as measured by B-cell count and immunophenotype in peripheral blood as determined by flow cytometry measured against MT-3724 serum concentrations at pre-specified time points [ Time Frame: up to 47 weeks (screening, day 1 of cycle 1, day 12 of cycle 1 (cycle is 21 days), and end of treatment, which should occur 10-14 days after the last dose) ]
    Evaluation of the pharmacodynamic profile of MT-3724

  16. Immunogenicity as measured by MT-3724 anti-drug antibody (ADA) titer [ Time Frame: up to 47 weeks (screening, day 1 of cycle 1, day 12 of cycle 1 (cycle is 21 days), and end of treatment, which should occur 10-14 days after the last dose) ]
    Evaluation of the Immunogenicity profile of MT-3724

  17. Quality of life as assessed through Euro-QoL Questionnaire (Part 3) [ Time Frame: up to 50 weeks (screening, day 1 of every other cycle (each cycle is 21 days), at end of treatment (which is 10-14 days after the last dose), and short-term follow-up visit (which is up to 33 days after the last dose) ]
    The Euro-Quality-of-Life-5 -dimension questionnaire assesses five states (mobility, self care, usual activities, pain / discomfort, and anxiety / depression) at five different levels - no problems, slight problems, moderate problems, severe problems, and extreme problems.

  18. Safety as measured by number of subjects with Adverse Events using CTCAE [ Time Frame: 21 days ]
    Safety measured by number of subjects with Adverse Events using CTCAE v 5.0 (Part 3)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women, age 18 years or older

Part 1:

• Histology based upon bone marrow biopsies and/or fine needle aspirates as the sole means of diagnosis are not acceptable. All subtypes of B-cell NHL may be considered for the MT-3724 dose escalation. Presence of lymphadenopathy and/or splenomegaly with histopathological evaluation of a lymph node biopsy consistent with CLL.

Part 2:

  1. Diffuse large B cell lymphoma (DLBCL). Histology based upon bone marrow biopsies and/or fine needle aspirates as the sole means of diagnosis are not acceptable.
  2. Subjects must have received at least one anti-CD20 antibody containing regimen that resulted in initial measurable response (partial or complete remission), followed by relapse/ recurrence.
  3. Life expectancy > 3 months.
  4. Eastern Cooperative Oncology Group (ECOG) performance score of ≤2.
  5. All lymphoma subjects are required to have measurable disease
  6. Patients must be at least 28 days past their last course of lymphoma
  7. Received any amount of anti-CD20 MAb therapy within the following periods before the start of treatment
  8. Received any amount of anti-CD20 MAb within the following periods before the start of treatment:

    1. Rituximab (Rituxan®): if a subject had received any amount of rituximab within 365 days of planned dose day 1 then a serum rituximab level must be negative (<500 ng/ml) at the screening period
    2. Obinutuzumab (Gazyva®): 184 days
    3. Ofatumumab (Arzerra®): 88 days
    4. ibritumomab tiuxetan (Zevalin®): 10 days
  9. Adequate kidney function, assessed by the estimated glomerular filtration rate (eGFR) ≥60 mL/min
  10. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods until the end of study visit.
  11. Patients with known central nervous system metastases may be enrolled if they have received radiotherapy, do not require chronic steroid therapy, have had computed tomography or magnetic resonance imaging of the brain within 1 month of study entry that shows stable disease and they have no neurological symptoms other than low grade neuropathy.

Exclusion Criteria:

  1. History of another cancer other than basal cell carcinoma or cervical intraepithelial neoplasia (CIN; i.e., cervical cancer in situ).
  2. Potential subjects cannot have experienced a significant (CTCAE Grade 3 or 4 with or without neutropenia) infection within 2 weeks of the first dose of MT-3724.
  3. Ongoing use of any approved or investigational antineoplastic therapies
  4. Systemic corticosteroid therapy at a prednisone dose > 20mg/day (or equivalent) within 14 days prior to study enrollment
  5. Potential subjects with pre-existing AEs at screening that are severe or life threatening by CTCAE, v. 4.03 should not be enrolled.
  6. Patients with uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to start of study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis may not be enrolled.
  7. Patients with a known history of drug abuse or any chronic neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic or renal disease (including a history of hemolytic uremic syndrome) that in the opinion of the Investigator would adversely affect study participation.
  8. Potential subjects must not have received any vaccines for 28 days prior to administration of their first dose of MT-3724 and should not receive any vaccine during the study or within 28 days after their last dose of MT-3724. The single exception to this exclusion is for the annual influenza (flu) vaccine which can be given up to 14 days prior to first dose.
  9. History of hypersensitivity to study drug or to compounds of a similar class, or whose past history suggests an increased potential for an adverse hypersensitivity reaction to MT-3724 should not be enrolled.
  10. Patients with known active Hepatitis A or C, HIV or a present history of Hepatitis B
  11. Potential subjects who have undergone allogeneic hematopoietic stem cell transplantation.
  12. Women who are pregnant or breastfeeding.
  13. Potential subjects who have had major surgery within 6 weeks prior to the first dose of study drug or have major surgery planned during the first 12 weeks post MT 3724 exposure.

Part 3

Inclusion Criteria:

  1. Subjects must have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma/World Health Organization (REAL/WHO) classification.
  2. Subjects must have received at least 2 standard of care regimens for NHL treatment.
  3. Subjects must have at least one tumor lesion at screening
  4. Subjects must have life expectancy of >3 months from the start of treatment.
  5. Subjects must have ECOG performance status of 0-2.
  6. Adequate kidney function
  7. QTcF (Fridericia) ≤480 ms determined as the average of three QTcF values from the triplicate ECG obtained at screening.
  8. LVEF ≥45% by MUGA or echocardiogram obtained at screening.
  9. Female patients of childbearing potential must not be pregnant.. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods until the end of study visit.
  10. Subject must be able to comply with all study-related procedures and medication use.

Exclusion Criteria:

  1. Received any amount of anti-CD20 MAb within the following periods before the start of treatment:

    1. Rituximab (Rituxan®/MabThera® or rituximab biosimilar): if administered within 12 to 37 weeks before the start of treatment, then serum rituximab level must be assessed during the screening and confirmed as negative (<500 ng/mL)
    2. Obinutuzumab (Gazyva®/Gazyvaro®): 184 days.
    3. Ofatumumab (Arzerra®): 88 days.
  2. Received approved or investigational treatment for NHL (except anti-CD20 MAb and radioimmunoconjugates) within 4 weeks before the start of treatment. Radioimmunoconjugates are excluded within 12 weeks before the start of treatment.
  3. Received radiation therapy to target lesions ) within 4 weeks before the start of treatment, unless the lesions exhibited objective progression between radiation therapy and screening

    a. Palliative radiation therapy to non-target lesions within 4 weeks before the start of treatment may be permitted at the investigator's discretion.

  4. Received systemic immunosuppressive agents (except prescribed corticosteroids at doses ≤20 mg/day prednisone equivalent) within 2 weeks before the start of treatment
  5. Received any vaccines except injectable flu (inactivated or recombinant) vaccine within 4 weeks before the start of treatment, or likely to require any vaccines except injectable flu vaccine at any time from the start of treatment until 28 days after the last dose of MT-3724.
  6. Received allogeneic stem cell transplant.
  7. Current evidence of CTCAE Grade ≥2 (significant) 1 toxicity before the start of treatment, except for hair loss and those significant toxicities permitted in other eligibility criteria. Subjects with significant permitted in other eligibility criteria. Subjects with significant
  8. History or current evidence of significant infection, systemic infection or wound within 2 weeks before the start of treatment.

    a. Subjects with significant infection that has stabilized or improved with oral antibiotics before the start of treatment may be eligible at the investigator's discretion.

  9. Known or suspected hypersensitivity to the study drug or excipients contained in the study drug formulation.
  10. Current evidence of hypersensitivity or other underlying illness requiring systemic corticosteroids at doses >20 mg/day prednisone equivalent
  11. Patients with known active Hepatitis C, HIV or a present history of Hepatitis B
  12. Current evidence of incomplete recovery from surgery or radiotherapy at screening, or planned surgery or radiotherapy from the start of treatment until the short term follow-up visit, except minor elective surgery or palliative radiation therapy to non-target lesions deemed acceptable by the investigator.
  13. History of cardiovascular, renal, hepatic or any other disease within ≤3 months before the start of treatment
  14. History of another primary malignancy within the past 3 years (except for ductal breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring treatment, and cervical carcinoma in situ) that required systemic drug therapy or radiotherapy.
  15. Current evidence of new or growing brain or spinal metastases during screening.
  16. Women who are pregnant or breastfeeding.
  17. History of non-adherence to the schedule of procedures or medication use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02361346


Contacts
Layout table for location contacts
Contact: Kristina Dabovic, PharmD kristina.dabovic@mtem.com
Contact: Tara Lehner, MS, PMP 215- 586-0118 tara.lehner@mtem.com

Locations
Layout table for location information
United States, Arizona
University of Arizona Recruiting
Tucson, Arizona, United States, 85724
Contact: Daniel Persky, MD         
Contact: Diane Rensvold    520-684-9055    drensvold@uacc.arizona.edu   
United States, New York
Memorial Sloan-Kettering Cancer Center Completed
New York, New York, United States
New York University Langone Medical Center Completed
New York, New York, United States
United States, North Carolina
University of North Carolina Completed
Chapel Hill, North Carolina, United States, 27599
United States, Texas
MD Anderson Cancer Center Completed
Houston, Texas, United States
UT Health San Antonio Cancer Recruiting
San Antonio, Texas, United States, 78229
Contact: Patricia Manea    210-450-1000    maneap@uthscsa.edu   
Principal Investigator: Adolfo Enrique Diaz         
Canada, Ontario
Cancer Centre of Southeastern Ontario at Kingston General Hospital Recruiting
Kingston, Ontario, Canada, K7L 2V7
Contact: Stephanie Willing    613-549-6666 ext 4187    Stephanie.Willing@kingstonhsc.ca   
Principal Investigator: Tara Baetz, MD         
Georgia
LLC ARENSIA Exploratory Medicine Recruiting
Tbilisi, Georgia, 0112
Contact: Nino Gvazava    995577555065    nino.gvazava@arensia-em.com   
Principal Investigator: Marina Zodelava, MD         
Moldova, Republic of
ARENSIA Exploratory Medicine, Recruiting
Chisinau, Moldova, Republic of, MD-2025
Contact: Adrian Crijanovschi, MD    373 78883396    adrian.crijanovschi@arensia-em.com   
Principal Investigator: Vasile Musteata, MD         
Ukraine
Medical Center of Limited Liability Company "Medical Centre Named by Academician Yurii Spizhenko Recruiting
Kyiv, Ukraine, 08112
Contact: Valentyn Moskalenko    38 066 941 1231    valentyn.moskalenko@arensia-em.com   
Principal Investigator: Tetiana Perekhrestenko         
Sponsors and Collaborators
Molecular Templates, Inc.

Layout table for additonal information
Responsible Party: Molecular Templates, Inc.
ClinicalTrials.gov Identifier: NCT02361346     History of Changes
Other Study ID Numbers: MT-3724_NHL_001
First Posted: February 11, 2015    Key Record Dates
Last Update Posted: July 29, 2019
Last Verified: May 2019
Keywords provided by Molecular Templates, Inc.:
CD20
immunotoxin
NHL
non-Hodgkin's lymphoma
lymphoma
cancer
antibodies
immunotherapy
safety
pharmacokinetics
maximum tolerated dose
MT-3724
relapsed
refractory
leukemia
CLL
SLL
DLBCL
efficacy
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Leukemia, Lymphoid
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Leukemia, B-Cell